Homepage > Company > Media > Pharma News > 2019 > Cegedim, Sanofi enter healthcare improvement RWD collaboration

Cegedim, Sanofi enter healthcare improvement RWD collaboration

Cegedim has announced that it is set to engage in an innovative collaboration on Real World Data for healthcare improvement in Europe with Sanofi.

The company has announced that it will provide Sanofi with information going back to 1994 for its full Real World dataset France & UK, powered by its proprietary THIN database.

Under the terms of the agreement, the state-of-the-art dataset will be provided and immediately available for processing with Artificial Intelligence technologies, which coupled with the strong support of Cegedim Health Data experts to Sanofi’s Real World Evidence and medical teams, will drive improvement in patient care in Sanofi’s numerous therapeutic areas.

The company says that its strategic collaboration with Sanofi, as one of the world’s leading pharmaceutical companies, confirms Cegedim’s leadership position as the most trusted healthcare data stakeholder and aims to accelerate the digital revolution in European health.

Jean-Claude Labrune, Cegedim chairman and CEO, said: “This historic collaboration with one of the global pharmaceutical industry’s leaders is proof of our European expertise on real world data and our ability to make it “actionable”. The depth of the history and robustness of the THIN data have led to more than 600 scientific articles”.

22nd May 2019

http://www.pharmatimes.com/

Read also

EC approves AstraZeneca’s Fasenra for EGPA treatment

The European Commission (EC) has approved AstraZeneca‘s Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangii...

Genprex reports positive preclinical gene therapy data

Genprex, Inc., a clinical-stage gene therapy company, announced positive preclinical results for its lead drug candidate, Reqorsa® (quratusugene ozeplasmid) Gene Therapy, at the recent EORTC-...

Astellas withdraws Europe ACP application for AMD treatment

Astellas Pharma has announced the withdrawal of its marketing authorisation application for IZERVAY (avacincaptad pegol, ACP) intravitreal solution to treat geographic atrophy (GA) sec...

New report demands greater understanding of the impact of change on academia

Digital Science, a technology company serving stakeholders across the research ecosystem, is today calling for greater awareness of the impact that a myriad of fast-developing technologies are having ...